AGI-134 was found to be safe and well tolerated with no dose-limiting toxicities observed Dose expansion part of study expected to commence shortly, with initial results expected by year-end 2020

BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

TEL AVIV, Israel, Sept...

Read on ››

Kode Biotech subsidiary, GlycoNZ (www.glyconz.com) has entered into a global distribution for the supply of glycoconjugates for research.

GlycoNZ products that were previously available from GlycoTech Corporation are now only available from www.glyconz.com.

We anticipate announcing a new distribution partner soon!

Read on ››

Tel Aviv, Israel – August 1, 2018 - BioLineRx Ltd...

Read on ››

The Board is very pleased to announce the appointment of Dr...

Read on ››



Original Article by Jamie Morton, Science Reporter, NZ Herald

  1. Biological "invisible ink" for anti-counterfeiting of pharmaceuticals and high-value clothing.

  2. Giving cells and viruses "address labels" on their surface so they can be "told" to go to a specific place in the body, including attacking cancer cells.

3...

Read on ››

Original Article by Jamie Morton, Science Reporter, NZ Herald

An Auckland scientist has invented molecules that can attach themselves to any surface in a few minutes and modify every type of cell or virus...

Read on ››

BioLineRx Buys U.K. Cancer Immunotherapeutics Firm Agalimmune

GEN News Highlights

Original Article

BioLineRx has bought U.K. anticancer company Agalimmune for $6 million in a 50/50 cash and shares-based deal to acquire its immunotherapy platform and late preclinical-stage compound AGI-134...

Read on ››

What is Kode Technology Video

Posted 3 years ago by Steve Henry

Watch the latest video of Kode Technology on YouTube

What is Kode Technology Video

Read on ››
Load more articles